The information on this site is designed for patients. If you are a healthcare
professional,
click here.
*
NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive
Disorder in adult patients who have failed to achieve satisfactory improvement from
one prior antidepressant medication at or above the minimal effective dose and duration
in the current episode.
|
|
|
Clinical trials have proven the effectiveness of NeuroStar TMS Therapy®
in treating patients who have not benefited from prior antidepressant medication.*
NeuroStar TMS Therapy was studied in adult patients suffering from Major Depressive
Disorder, all of whom had not received satisfactory improvement with previous therapies.
NeuroStar TMS Therapy has not been studied in patients who have not received prior
antidepressant treatment. Its effectiveness has also not been established in patients
who have failed to receive benefit from two or more prior antidepressant medications
at minimal effective dose and duration in the current episode.
An Effective Option for Treating Major Depressive Disorder
In a controlled clinical trial comparing active treatment with the NeuroStar TMS
Therapy® system to an inactive device, patients treated with active
NeuroStar TMS Therapy experienced a 22.1% average reduction of their depression
symptoms, compared to a 9% average reduction of depression symptoms in patients
receiving inactive treatment.1
Patients treated with NeuroStar® also experienced significant improvement
in anxiety and physical symptoms (such as appetite changes, aches and pains,
and lack of energy) associated with depression.1
In a study most like real world clinical practice where all patients received active
treatment, approximately half of the patients treated with NeuroStar TMS Therapy
experienced significant improvement in their depression symptoms. About a third
of the patients treated with NeuroStar TMS Therapy experienced complete symptom
relief at the end of six weeks.1
NeuroStar TMS Therapy has not been studied in patients who have not received prior
antidepressant treatment. Its effectiveness has also not been established in patients
who have failed to receive benefit from two or more prior antidepressant medications
at minimal effective dose and duration in the current episode.
View safety data.
References:
- Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation
(TMS) in the treatment of pharmacoresistant depression: synthesis of recent data.
Psychopharm Bull. 2009, 42(2): 5-38.
|
|